Building the Community Oncology Practice of the Future Demands a Comprehensive Approach
As cancer care continues to shift away from a fee-for-service model to a value-based care model, clinicians and institutions will need to be adaptable and innovative to build effective community oncology practices of the future.
Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy
Novel strategies to modulate the microbiota are now an area of robust investigation
Beyond the Clinic: Leveraging Research to Tackle Lung Cancer Disparities
Lung cancer remains the most common cause of cancer death in the United States.
Tissue Is Still the Issue: Pathology Expert Discusses Clinical Needs in the Molecular Era
Lynette M. Sholl, MD, discusses why cancer pathologists still want better tissue samples.
Targeted Treatment Arsenal for Myelofibrosis Set to Explode
Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis.
Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma
The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.
Pragmatic Clinical Trials Can Play a Key Role in Oncology
Pragmatic clinical trials “inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice.”
Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer
Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
2 Clarke Drive Cranbury, NJ 08512